摘要:

Eleven children aged 0.6–17 years with preterminal chronic renal failure and anemia (mean serum creatinine concentration 4.8 mg/dl; mcan hemoglobin concentration 7.9 g/dl) were treated with sc injections of recombinant human crythropoictin (EPO, initial dose 150 U/kg/week) over a mean period of 13 months. When a target hemoglobin concentration of 11.5–13.5 g/dl was reachcd, the dose was adapted. Iron deficiency was corrected. Hemoglobin concentration increased by>2 g/dl in all patients within 14–119 (mean 45) days. The last maintenance dose ranged between 75 and 300 (mean 133) U/kg/ wcek. No major adverse effects were observed, except for hypertension which occurred in about half of the patients and necessitated interruption of EPO in one child with advanced renal failure. Additional antihypertensive drugs were given to five patients. Body height increascd in two patients by 0.6 and 1.3 SDS/year, respectively. In six patients with a mean observation period of 14 months before and 16 months after the start of EPO, the mean slope of the reciprocal serum creatinine concentration curve improved slightly (p = 0.05). The proposed schedule appears to be safe for the treatment of renal anemia in most pre‐dialysis paticnts. Frequent monitoring of hemoglobin, blood pressure, serum crcatinine and ferritin is r

ISSN:0803-5253    

DOI:10.1111/j.1651-2227.1993.tb12607.x

出版商:Blackwell Publishing Ltd    

年代:1993

数据来源: WILEY

摘要:

Subcutaneous recombinant human erythropoietin (rHuEpo) treatment of renal anemia was performed in four boys and eight girls on CAPD, aged 0.8–12.5 (mean 7.4) years. In contrast to previous studies, our therapeutic goal was not set with a hematocrit of 30% but with full correction of anemia. Following a maximum weekly rHuEpo dosage of median 120 (range 100–240) IU/kg body weight, hcmatocrit increased in 10 children from 24 (14–29)%) within 12 (4–17) weeks to 40.1 (33.5–48.4)%. The weekly increase in hematocrit was 1.27 (0.5–3.1)%. The corrected reticulocyte count increased from I.3 (0.7–1.8)% to 2.3 (1.4–3.9)% within 4 (2–6) weeks. Eight childrcn fulfilled the protocol; six with an uncomplicated course were able to maintain a hematocrit of 37.1 (35.1–42.7)% with only one sc medication per week of approximately two‐thirds of their highest weekly rHuEpo dosage. No serious adverse effect of rHuEpo

ISSN:0803-5253    

DOI:10.1111/j.1651-2227.1993.tb12608.x

出版商:Blackwell Publishing Ltd    

年代:1993

数据来源: WILEY

摘要:

We measured plasma salbutamol concentrations in 35 children with acute asthma attacks before and after nebulizer therapy. The main finding was that older children had higher concentrations than younger children, despite similar dosage regimens. There was no influence of severity of the asthma attack on the following measures: pre‐ and post‐nebulizer concentrations, absolute and percentage change in salbutamol levels with therapy. We conclude that the theoretical risks of high concentrations in young children were not found and we suggest that the very young may indeed require higher doses due to possible problems in nebulizer technique or differences in kinet

ISSN:0803-5253    

DOI:10.1111/j.1651-2227.1993.tb12609.x

出版商:Blackwell Publishing Ltd    

年代:1993

数据来源: WILEY

摘要:

Suskind RM and Lewinter‐Suskind L editors.Textbook of Pediatric Nutrition, 2nd ed. Ncw York: Raven Prcss, 190

ISSN:0803-5253    

DOI:10.1111/j.1651-2227.1993.tb12610.x

出版商:Blackwell Publishing Ltd    

年代:1993

数据来源: WILEY

摘要:

The objective of the present study was to measure plasma Concentrations of the gastrointestinal hormones gastrin, somatostatin and cholecystokinin in plasma of children with recurrent abdominal pain. since these hormones affect gastrointestinal function. Forty‐four children (7–16 years old) with recurrent abdominal pain and 36 control children (matched for age and sex) participated in the study. In a blood sample collected after an overnight fast, gastrin, somatostatin and cholecystokinin concentrations werc measured by radioimmunoassay. The children with recurrent abdominal pain had higher plasma cholecystokinin levels (p<0.001) than the controls. Whether or not this aberration is related to the clinical symptoms of children with recurrent abdominal pain remains to be establis

ISSN:0803-5253    

DOI:10.1111/j.1651-2227.1993.tb12611.x

出版商:Blackwell Publishing Ltd    

年代:1993

数据来源: WILEY

摘要:

During the period 1984–1991. 21 infants with biliary atresia were treated with Kasai's portoentcr‐ostorny. The median survival in infants operated on before the age of 60 days (55 (range 5–82) months) was significantly longer than the survival of children operated on after the age of 60 days (15 (1.5 38) months). At present there arc 10 survivors with a median age of 54 (17–96) months: 6 with portoenterostomy and 4 after liver transplantation. Eight patients died of progressive liver failure and 3 died of causes not related 10 biliary atresia. Apart from blood tests, ultrasonography was the most important investigation bcfore laparotomy in infants with cholestatic jaundice. Scintigraphy and liver biopsy added no further decisive information. Because early diagnosis and surgical treatment is important. only the well documented presence of a normal gallbladder can warrant postponement of an op

ISSN:0803-5253    

DOI:10.1111/j.1651-2227.1993.tb12612.x

出版商:Blackwell Publishing Ltd    

年代:1993

数据来源: WILEY

摘要:

All cases of sudden death of individuals between the ages of one and five years examined at the Forensic Institute, Copenhagen, in a 10‐year period were identified to assess the impact of sudden unexplained death in this age group. Of a total of 68 cases, 27 cases were due to accidents, there were 13 cases of homicide, 27 cases were sudden natural deaths and in 1 case the manner of death was uncertain. The autopsy records and histological sections in the 27 cases of natural death were reviewed; the cause of death was not explained in 11 of these cases (40%). Seven cases were previously considered to be caused by infectious disease or aspiration. Criteria for classification are discusse

ISSN:0803-5253    

DOI:10.1111/j.1651-2227.1993.tb12613.x

出版商:Blackwell Publishing Ltd    

年代:1993

数据来源: WILEY

ISSN:0803-5253    

DOI:10.1111/j.1651-2227.1993.tb12614.x

出版商:Blackwell Publishing Ltd    

年代:1993

数据来源: WILEY

ISSN:0803-5253    

DOI:10.1111/j.1651-2227.1993.tb12615.x

出版商:Blackwell Publishing Ltd    

年代:1993

数据来源: WILEY

摘要:

Biosynthetic insulin‐like growth factor I (IGF‐I) was administered subcutaneously twice a day for one year to a patient with isolated growth hormone deficiency (IGHD) type IA with high titres of anti‐GH antibody (up to 1:1 000 000). During IGF‐I therapy he showed good linear growth without any side effects, such as hypoglycemia and anti‐IGF‐I antibody formation. Administration of IGF‐I to IGHD type IA with poor response to GH therapy appears to have a beneficial eff

ISSN:0803-5253    

DOI:10.1111/j.1651-2227.1993.tb12616.x

出版商:Blackwell Publishing Ltd    

年代:1993

数据来源: WILEY